European Health Data Space: an important tool to bridge the digital gap

The European Commission published today its proposal to create a European health data space (EHDS). The American Chamber of Commerce to the European Union (AmCham EU) supports this initiative that seeks to further bridge the digital gap in the life science and healthcare sectors. A common European approach for the use and re-use of health data has the potential to make the development of innovative health technologies at the scale of the EU easier and boost the creation of new treatments, therapies and medical devices.

News
2 May 2022
Healthcare
European Health Data Space: an important tool to bridge the digital gap

The European Commission published today its proposal to create a European health data space (EHDS). The American Chamber of Commerce to the European Union (AmCham EU) supports this initiative that seeks to further bridge the digital gap in the life science and healthcare sectors. A common European approach for the use and re-use of health data has the potential to make the development of innovative health technologies at the scale of the EU easier and boost the creation of new treatments, therapies and medical devices.

In order to live up to the expectations of the EHDS, the co-legislators will need to ensure that the current lack of interoperability and standards is overcome and that a broad set of stakeholders – such as the life science and healthcare industry as well as third countries – will be included in the scope of the EHDS.

The EHDS, which is the first initiative of its kind, needs to carefully balance the needs for both legal certainty and adaptability required in the rapidly-changing domain of data science, in order to ensure that all stakeholders – patients, clinicians, payors, regulators and industry partners — can fully engage in and benefit from the EHDS. This will be best achieved through open, transparent and structured stakeholder involvement throughout the development and implementation of the EHDS. Furthermore, in order to foster trust in the EHDS, citizens need to be supported in exercising their rights and guided on the implications of new concepts such as data altruism.

The EHDS should ensure a consistent and efficient framework for the reuse of health data in order to support the development, access to and adoption of innovative solutions in Europe’s health systems, advancing health equity in the EU and globally. This framework must consider and promote international collaboration including third-country access to health data, noting that health threats know no borders, as exemplified by the COVID pandemic. AmCham EU is committed to the success of the EHDS as an opportunity to achieve better health for all citizens and address existing and future global health challenges.  

Related items

News
27 Oct 2025

Advancing EU health policy through competitiveness and innovation

On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda. 

Healthcare
Read more
Read more about Advancing EU health policy through competitiveness and innovation
News
9 Oct 2025

Advancing European healthcare in Strasbourg

From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation. 

Healthcare
Read more
Read more about Advancing European healthcare in Strasbourg
How the Critical Medicines Act will strengthen Europe’s life sciences sector
News
4 May 2025

How the Critical Medicines Act will strengthen Europe’s life sciences sector

On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU. 

Healthcare
Read more
Read more about How the Critical Medicines Act will strengthen Europe’s life sciences sector